An observational study in Acromegaly, sponsored by Camurus AB. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Camurus AB · Observational
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.
This study's planned enrollment of 200 is above the median of 100 across 81 observational studies indexed under Acromegaly.
Browse Acromegaly studies →Camurus AB is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will enroll patients with acromegaly who are considered for treatment with octreotide subcutaneous depot and patients with acromegaly who have already initiated octreotide subcutaneous depot treatment. The study will be conducted in Germany, the UK, and the US.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Commercially available octreotide subcutaneous depot treatment administered by participants for a maximum duration up to 2 years in the study
Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information.
Time frame: From enrollment to the end of treatment at 2 years
Change in absolute IGF-1 levels and relative IGF-1 (IGF-1/ULN) over time.
Time frame: From enrollment to the end of treatment at 2 years
Change in proportion of participants with IGF-1 ≤1×ULN over time.
Time frame: From enrollment to the end of treatment at 2 years
Change in GH levels over time.
Time frame: From enrollment to the end of treatment at 2 years
Change in proportion of participants with GH levels <1.0 μg/L over time.
Time frame: From enrollment to the end of treatment at 2 years
Changes in symptoms of acromegaly over time, as measured by the Acromegaly Index of Severity (AIS) scale.
The clinician-reported AIS Overall Score ranges from 0 to 18, where a higher score indicates more severe symptoms.
Time frame: From enrollment to the end of treatment at 2 years
Changes in QoL over time, as measured by the Acromegaly Quality of Life Questionnaire (AcroQoL).
The AcroQoL domain scores range from 0 to 100, where a higher score indicates better quality of life.
Time frame: From enrollment to the end of treatment at 2 years
Changes in QoL over time, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM).
The TSQM domain scores range from 0 to 100, where a higher score indicates greater treatment satisfaction.
Time frame: From enrollment to the end of treatment at 2 years
Changes in QoL over time, as measured by the Assessment of Acromegaly Symptoms (AAS) questionnaire.
The patient-reported AAS total score ranges from 0 to 48, where a higher score indicates more severe symptoms.
Time frame: From enrollment to the end of treatment at 2 years
Incidence of octreotide SC depot non-related AEs and incidence of laboratory abnormalities using the CTCAE grading scale.
Time frame: From enrollment to the end of treatment at 2 years
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Camurus AB